GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Genomic Valley Biotech Ltd

Genomic Valley Biotech: Q2 & H1 FY27 Unaudited Financial Results Approved

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 30 Oct 2026, 06:13 PM IST  ·  BSE ID: 473a01ff-c960-4672-af7f-f5721a1831b7
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved its financial performance report for the past six months ending September 2026.
🤖 AI Summary
  • Genomic Valley Biotech Board approved standalone unaudited financial results for quarter and half year ended September 30, 2026.
  • The Board meeting, held October 30, 2026, started at 05:15 P.M. and concluded at 05:45 P.M.
  • Andros & Co., Chartered Accountants, issued a Limited Review Report on these unaudited financial statements.
  • The results are submitted in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this approval filing alone.
👤
Who Is Affected
All shareholders are informed that the company's financial results for Q2 and H1 FY27 have been approved by the Board and reviewed by statutory auditors.
🔍
Management Signal
The approval of financial results indicates management's adherence to regulatory timelines for disclosing periodic financial performance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Company's next filing — review the actual Q2 and H1 FY27 financial results data.
Upcoming Board meeting — note any new business decisions or operational updates.
Analyst calls/presentations — check for management commentary on these results.
LOW RISK The filing confirms a routine regulatory compliance event without new risks.
💡 Investor Takeaway
Genomic Valley Biotech's Board of Directors approved the unaudited standalone financial results for the quarter and half year ended September 30, 2026. The Limited Review Report by Andros & Co. accompanies these results, confirming compliance with SEBI regulations.
📅 Company Track Record
Genomic Valley Biotech previously informed BSE on August 6, 2026, about a Board meeting scheduled for August 14, 2026, to approve Q1 FY27 unaudited results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What financial period do the approved results for Genomic Valley Biotech cover?
The approved results cover the unaudited standalone financial performance for the quarter and half year ended September 30, 2026.
When did the Board meeting of Genomic Valley Biotech to approve results take place?
The Board meeting was held on Wednesday, October 30, 2026, commencing at 05:15 P.M. and concluding at 05:45 P.M.
Who reviewed the unaudited financial results for Genomic Valley Biotech?
Andros & Co., Chartered Accountants, provided the Limited Review Report on the unaudited financial results.
Under which SEBI regulation was this filing made by Genomic Valley Biotech?
This intimation regarding the outcome of the Board meeting was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.